Hints and tips:
...It was unbelievable,” said Alisha Alaimo, Biogen’s North America head....
...Demaré declined to comment directly on the Biogen talks, but said that at the far larger AstraZeneca Soriot could create “a few Biogens in the years to come”. Biogen declined to comment on the talks....
...Its decision against widely covering Aduhelm, another Alzheimer’s drug developed by Biogen and Eisai, which secured a form of conditional approval two years ago, contributed to Biogen scrapping its commercial...
...Biogen later dropped the price to $28,200, according to the report....
...The US Food and Drug Administration in January approved lecanemab, a drug co-developed by Japanese drugmaker Eisai and US biotech Biogen, under an accelerated process....
...Investors responded by bidding up Biogen and Eisai shares by 47 per cent and 66 per cent respectively....
...Christopher Viehbacher, Biogen’s chief executive, told an audience at a biotech conference in Boston that the company would look at whether it should file its own lawsuit against the IRA....
...A genetically targeted treatment for motor neurone disease developed by Biogen has slowed the progression of the disease in a clinical trial and even improved the symptoms of some patients....
...Shares in Biogen and Eisai surged on Wednesday after the pharma groups said they would apply for regulatory approval for a new Alzheimer’s drug following a late-stage clinical trial that showed it slowed...
...Both Roche’s gantenerumab and lecanemab, co-developed by Eisai and Biogen, are monoclonal antibody treatments based on the hypothesis....
...Lecanemab originated with BioArctic, a small Swedish company that collaborated with Eisai and then Biogen to take it through clinical trials....
...Last week Biogen disclosed that it paid Vounatsos $17.6mn in 2021, down from $18.6mn in the previous year....
...The phase 3 trial is being led by Eisai, a Tokyo-based pharmaceutical company that has partnered US biotech Biogen to develop lecanemab....
...BP recorded its highest quarterly earnings in more than a decade, Italy’s prime minister, Mario Draghi, called on Brussels to abandon the requirement for unanimity on foreign policy decisions, and Biogen...
...Biogen said it believed that about 50,000 patients might start treatment with Aduhelm in 2022....
...Biogen is appealing....
...The panel is expected to give its formal decision next month, Biogen said....
...Biogen hopes the treatment will become a blockbuster drug capable of boosting the company’s revenue at a time when many of its existing products face competition....
...Michel Vounatsos, chief executive of Biogen, said in an earnings call on Thursday: “I want to be clear that Biogen stands behind the integrity of the review process.”...
...US biotech giant Biogen promises to change that. This week US regulators gave the greenlight to its new drug, called aducanumab....
...Biogen says the drug clears amyloid plaques from the brain and in turn alters the course of the disease....
...In an interview, Eisai chief executive Haruo Naito said the Japanese group and Biogen were preparing steps to make the drug more widely accessible....
...The stock price of Japanese drugmaker Eisai, Biogen’s development partner on aducanumab, surged 56 per cent....
...Shares in Biogen fell 3 per cent in New York on Friday....
...Biogen’s shares closed up 38 per cent at $395.85 on Monday, a six-year high....
International Edition